Table 6.
Group | Mfn2 | Procollagen | ||
---|---|---|---|---|
1A1 | 1A2 | 3A1 | ||
Sh (n = 10) | 0.39 ± 0.07 | 0.99 ± 0.17 | 1.23 ± 0.32 | 1.06 ± 0.19 |
shNC (n = 10) | 0.70 ± 0.14 | 0.67 ± 0.16 | 0.92 ± 0.14 | 0.58 ± 0.12 |
Control (n = 10) | 0.68 ± 0.09 | 0.57 ± 0.16 | 0.88 ± 0.18 | 0.55 ± 0.13 |
F | 26.661 | 18.277 | 6.606 | 36.178 |
Psh-shNC | <0.001 | <0.001 | 0.017 | <0.001 |
Psh-control | <0.001 | <0.001 | 0.007 | <0.001 |
PshNC-control | 0.838 | 0.445 | 0.928 | 0.897 |
P<0.05 indicates significant difference, one-way ANOVA test and univariate analysis. The expression levels of Mfn2 were downregulated in sh group, but the expression levels of procollagen were increased in sh group. POP: Pelvic organ prolapse; Mfn2: Mitofusin 2; sh: POP fibroblasts that were transfected with shRNA positive interference lentiviral sequence; shNC: POP fibroblasts that were transfected with shRNA negative control lentiviral sequence; Control: POP fibroblasts in the absence of lentiviral infection; ANOVA: Analysis of variance.